Lymph node (LN) lesion that measures at least  dimension as ?. centimeter (cm) in the short axis;
The presence of known lung or liver metastases greater than . cm in the long axis diameter
The presence of lymphadenopathy greater than  cm in the short-axis diameter
T, node positive or advanced rectal adenocarcinoma. Node positivity defined as nodes greater than cm in short axis with loss of uniform cortex/fatty hilum.
Measurable disease according to RECIST . and irRECIST. At least one lesion of at least . cm in the long-axis diameter for a non-lymph node or at least . cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST . and irRECIST using either computed tomography (CT) or magnetic resonance imaging (MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least . cm
Patients must have measurable disease, defined as at least one lesion above and below the diaphragm or stage  disease that can be accurately measured in at least one dimension; lymph nodes should be considered abnormal if the long axis is > . cm, regardless of the short axis
Pancreatic target tumor diameter of ? . cm (shortest axis) to ? . cm (longest axis) and a minimum tumor volume of . cc as qualified by the central reading center
At least  measurable lesion according to modified RECIST Version . (non?nodal lesions must be ?. cm in the long axis or ?double the slide thickness in the long axis) within  days prior to the first dose of study drug.
Measurable disease by RECIST v. criteria (tumor >=  cm in longest diameter on axial image on computed tomography [CT] or magnetic resonance imaging [MRI] and/or lymph node(s) >= . cm in short axis on CT or MRI) on baseline imaging
At least  measurable site of disease according to Revised Response Criteria for Malignant Lymphoma (Cheson Criteria); the site of disease must be greater than . cm in the long axis regardless of short axis measurement or greater than . cm in the short axis regardless of long axis measurement, and clearly measurable in  perpendicular dimensions
No radiographic evidence of lymph node positive disease as per Response Evaluation Criteria in Solid Tumors (RECIST) . (>=  mm short axis diameter); lymph node positive disease is defined as clinical lymphadenopathy on staging computed tomography (CT) or magnetic resonance imaging (MRI) greater than . cm in the short axis; if a lymph node is greater than . cm, it has to be biopsy proven negative for the patient to be eligible
Lymphadenopathy exceeding  cm in short-axis diameter
Subjects deemed to have residual hilar or mediastinal lymph node disease (defined as nodal size >  cm in short-axis diameter on CT scan); nonmalignant etiologies for enlarged lymph nodes may be evaluated per standard clinical practice
Patients with contralateral hilar involvement (greater than . cm on short axis or positive on PET scan, or biopsy-proven)
Must have at least  node greater than . cm in short axis diameter
Clinically or radiographically evident structural disease; patients with measurable disease and those with only non-measurable (non-target) structural disease (according to modified Response Evaluation Criteria in Solid Tumors [RECIST] version [v] . criteria) are eligible;\r\nNOTE : Modification of the RECIST v. measurable disease criteria includes a change in the definition of what is considered a measurable malignant lymph node; a malignant lymph node is considered measurable if any of the following apply:\r\n* It is noted to be RAI-avid on radioactive iodine imaging (diagnostic or post-therapy whole body scans acceptable) and it measures >=  cm in the long axis,\r\n* It is pathologically proven to be involved with thyroid cancer (by cytology or pathology) and it measures >=  cm in the long axis, or\r\n* Its short axis is >= . cm when assessed by computed tomography (CT) scan\r\nNOTE : Patients only with biochemical evidence of disease without structural evidence of cancer are not eligible for this study
At least  lesion of ?. centimeter (cm) in the longest diameter for a non-lymph node or ?. cm in the short-axis diameter for a lymph node that is serially measurable according to Response Evaluation Criteria In Solid Tumors (RECIST) . using computerized tomography/magnetic resonance imaging (CT/MRI).
Measurable disease is defined as at least one lesion that can be accurately measured with the longest diameter as >= . cm by computed tomography (CT) scan or >= . cm with calipers by clinical examination; the exceptions to these criteria are pathologic lymph nodes, which must be >= . cm in the short axis when assessed by CT scans with slice thickness =< . cm
Non-measurable lesions include the following: small lesions (longest diameter < . cm for all lesions other than pathologic lymph nodes, which are >= . cm and < . cm in the short axis), bone metastases, pleural effusions, pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, lymphangitis pulmonis, lymphangitis cutis, and abdominal masses not followed by CT or magnetic resonance imaging (MRI)
Patients with pelvic and/or retroperitoneal lymph nodes < . cm in short axis are eligible
Have measurable disease based as defined by at least one lesion that can be measured in least  perpendicular dimensions and measures at least . cm in its long axis
Evidence of nodal disease greater than or equal to  mm in short axis as these findings are concerning for metastases that would not be targeted with radium- alone (Arm B); however, lymph nodes with short axis measurements between .- cm that have not enlarged more than mm (to account for reader variability) over the last  months and which are not inducing symptoms, causing obstruction, or in the opinion of the investigator pose a risk of impending obstruction of any structures, will be allowed
A PET/computed tomography (CT) scan is required; patients with hilar or mediastinal lymph nodes with short axis diameter =<  cm and no abnormal hilar or mediastinal uptake on PET will be considered N; patients with >  cm short axis diameter of hilar or mediastinal lymph nodes on CT or abnormal PET (including suspicious but non-diagnostic uptake) may still be eligible if directed tissue biopsy of all abnormally identified areas are negative for cancer; solitary pulmonary lesions =<  mm will not be considered significant
Have measurable disease at Screening by computed tomography (CT) (or magnetic resonance imaging [MRI]) as defined by at least  lesion of greater than or equal to . cm in the longest diameter for a non-lymph node or greater than or equal to . cm in the short-axis diameter for a lymph node that is serially measurable according to the modified RECIST criteria
Nonhepatic lesion c. Lymph node (LN) lesion that measures at least one dimension as greater than or equal to . cm in the short axis, except for porta hepatis LN that measures greater than or equal to . cm in the short axis d. Non-nodal lesion that measures greater than or equal to . cm in the longest diameter Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.
Participants must have measurable disease, including at least one of the following: an absolute B cell count > /uL, OR lymphadenopathy with at least one lymph node >  cm in long axis, OR palpable splenomegaly, OR cytopenias (hemoglobin [Hb] <  g/dL or platelets <  K) together with bone marrow infiltration
Measurable disease (NHL: At least  measurable site of disease [>. centimeter [cm] in the long axis regardless of short axis measurement or >. cm in the short axis regardless of long axis measurement, and clearly measurable in  perpendicular dimensions])
Lymphadenopathy exceeding  cm in short-axis diameter
Malignant lymphadenopathy exceeding  cm in short-axis diameter.
Malignant lymphadenopathy with lymph nodes exceeding  cm in short axis diameter
Lymphadenopathy with lymph nodes exceeding  cm in short axis diameter
Patients must have had node negative (pN) disease found at the time of surgery; if a nodal dissection was not performed at the original surgery then patients must be N, as defined by a lack of radiographic or clinical evidence of local-regional tumor recurrence, including pelvic lymph nodes >=  cm in short-axis diameter
Radiographic or clinical evidence of regional tumor nodal recurrence, including pathological pelvic lymph nodes >=  cm in short-axis diameter; radiographic evidence of distant metastases is also an exclusion
At least one lesion of at least . cm in the long-axis diameter for a non-lymph node or at least . cm in the short-axis diameter for a lymph node which is serially measurable according to Response Evaluation Criteria in Solid Tumors . (RECIST .) using either computerized tomography (CT) or magnetic resonance imaging (MRI). If there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least . cm.
Patients with pelvic and/or retroperitoneal nodes <  cm in short axis are eligible as they are not considered to have definitive metastases
Measurable disease according to RECIST .; at least one lesion of at least . cm in the long-axis diameter for a non-lymph node or at least . cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST . using either computed tomography (CT) or magnetic resonance imaging (MRI); if there is only one target lesion and it is a non-lymph node, it should have a longest diameter of at least . cm
Presence of measurable disease meeting the following criteria:\r\n* At least one lesion of >= . cm in long axis diameter for non-lymph nodes or >= . cm in short axis diameter for lymph nodes that is serially measurable according to RECIST . using either computerized tomography or magnetic resonance imaging or panoramic and close-up color photography with caliper measurement; if there is only one target lesion and it is a not a lymph node, it should have a long-axis diameter of at least . cm\r\n* Lesions that have had radiotherapy must show radiographic evidence of disease progression based on RECIST . may be deemed a target lesion
Baseline fludeoxyglucose F  (FDG)-positron emission tomography (PET) scans must demonstrate positive lesions compatible with computed tomography (CT) defined anatomical tumor sites\r\n* CT scan showing at least:\r\n**  or more clearly demarcated lesions/nodes with a long axis > . cm and short axis >= . cm OR\r\n**  clearly demarcated lesion/node with a long axis > . cm and short axis >= . cm
Patients with measurable disease per RECIST . criteria\r\n* At least one lesion of >= . cm in long-axis diameter for non lymph nodes or >= . cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST . using either computerized tomography (CT) or magnetic resonance imaging (MRI)\r\n* Lesions that have had radiotherapy must show evidence of progressive disease (PD) based on RECIST . to be deemed a target lesion
Measureable disease, defined as at least one bi-dimensionally measurable non-lymph node lesion greater than or equal to (>/=)  centimeter (cm) in long-axis diameter on spiral computed tomography (CT) scan or at least one bi-dimensionally measurable lymph node measuring >/= . cm in short-axis diameter on spiral CT scan
At least one lesion of greater than or equal to . cm in long-axis diameter for non lymph nodes or greater than or equal to . cm in short-axis diameter for lymph nodes which is serially measurable according to RECIST . using either computerized tomography or magnetic resonance imaging or panoramic and close-up color photography.
Radiographically measurable disease, defined as:  or more clearly demarcated lesions/nodes with a long axis >. cm and short axis ?.cm. OR  clearly demarcated lesion/node with a long axis >. cm and short axis ?.cm.
Definite evidence of metastatic prostate cancer, in the opinion of the treating physician; pelvic and retroperitoneal lymph nodes < . cm in short axis are allowed
Diagnosis\r\n* Arm : subject must have a documented diagnosis of prostate cancer with evidence of lymph node involvement (with a short axis diameter of >= . cm on a conventional computed tomography [CT] or MRI obtained within  weeks of the ferumoxytol imaging procedure)\r\n* Arm : subject must have a documented diagnosis of bladder cancer (transitional cell carcinoma) with evidence of lymph node involvement (with a short axis diameter of >= . cm on a conventional CT or MRI obtained within  weeks of the ferumoxytol imaging procedure)\r\n* Arm : subject must have a documented diagnosis of kidney cancer (all renal cell cancer types) with evidence of lymph node involvement (with a short axis diameter of >= . cm on a conventional CT or MRI obtained within  weeks of the ferumoxytol imaging procedure)
CT scans showing involvement of  or more clearly demarcated lesions with a long axis > . cm and short axis >= . cm
Measurable disease meeting the following criteria:\r\n* At least  lesion of >= . cm in the longest diameter for a non-lymph node or >= . cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST . using computerized tomography/magnetic resonance imaging (CT/MRI); if there is only one target lesion and it is a non-lymph node, it should have a longest diameter of >= . cm\r\n* Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST . to be deemed a target lesion
Measurable disease (at least one lesion on radiographic or exam assessment measuring >=  cm in longest axis)
Lymph node (LN) lesion that measures at least one dimension as ?. cm in the short axis, except for porta hepatis LN that measures ?. cm in the short axis
At least  lesion of ?. cm in the longest diameter for a non-lymph node or ?. cm in the short-axis diameter for a lymph node that is serially measurable according to RECIST . using CT/MRI.
At least  lesion of ?. cm in the longest diameter for a non-lymph node or ?. cm in the short-axis diameter for a lymph node that is serially measurable according to Response Evaluation Criteria in Solid Tumors (RECIST .) using computed tomography/magnetic resonance imaging (CT/MRI). If there is only  target lesion and it is a non-lymph node, it should have a longest diameter of ?. cm.
